In vitro
This study developed and validated a novel analytical strategy for characterizing how BPC-157 — a peptide classified as a doping agent — is metabolized in laboratory (in vitro) conditions. The researchers used stable isotope labeling (¹³C/¹⁵N-labeled BPC-157) combined with ultra-high-performance liquid chromatography–high-resolution mass spectrometry (UHPLC-HRMS) to systematically identify metabolites without needing prior knowledge of metabolic pathways. Using two in vitro incubation models, the study identified nine total metabolites: eight arising from conventional amide-bond cleavage and one from a previously unreported metabolic pathway. The team then developed and validated a detection method for BPC-157 and five key metabolites in human urine, achieving detection limits of 0.01–0.11 ng/mL and strong quantitative performance. Importantly, this was an entirely in vitro study; no human participants or animals were involved, meaning the metabolic profile observed may not fully reflect what occurs in the human body. The findings are primarily relevant to anti-doping laboratories seeking improved detection targets and analytical workflows, and do not speak to the biological effects or clinical utility of BPC-157.
Molecules (Basel, Switzerland) · Oct 2023DOI ↗ In vitro
This study investigated whether two growth hormone secretagogues (GHSs) — hexarelin and JMV2894 — could protect neural cells from oxidative stress in the context of amyotrophic lateral sclerosis (ALS). The researchers used human neuroblastoma cells (SH-SY5Y) engineered to express the SOD1-G93A mutant protein, a model relevant to familial ALS. Cells were exposed to hydrogen peroxide (H₂O₂) to simulate oxidative stress, with or without GHS co-treatment. The study found that both hexarelin and JMV2894 appeared to protect cells from H₂O₂-induced cytotoxicity by activating molecular pathways associated with the regulation of apoptosis and cell survival. The authors suggest these compounds may have antioxidant and neuroprotective properties worth exploring for ALS therapy. Key limitations include that this is a cell-based (in vitro) study only, using a cancer-derived cell line rather than primary motor neurons, and no animal or human data were generated. The authors themselves acknowledge the need for further work to clarify mechanisms and develop improved GHS candidates before any translational conclusions can be drawn.
International journal of molecular sciences · Jan 2023DOI ↗ In vitro
This study, motivated by anti-doping enforcement, investigated the in vitro metabolism and urinary detection of four synthetic growth hormone releasing hormone (GHRH) analogs: sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex (DAC). Because these compounds are banned by the World Anti-Doping Agency (WADA) yet rarely detected in accredited laboratory samples—likely due to low urinary concentrations and poorly understood metabolism—researchers used in vitro methods to identify 19 major metabolites. These metabolites were synthesized, purified, and characterized in-house to serve as reference materials. Using these standards alongside commercially available parent compounds and one known sermorelin metabolite (sermorelin(3-29)-NH₂), the team developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method applied to fortified (spiked) urine samples. Limits of detection were generally at or below 1 ng/mL, meeting WADA's required performance threshold. Key limitations include the in vitro nature of the metabolism work, meaning real-world in vivo metabolite profiles in humans may differ, and no actual athlete or clinical urine specimens were analyzed. The study advances analytical capability for anti-doping testing but does not evaluate physiological or clinical effects of these peptides.
Drug testing and analysis · Nov 2021DOI ↗ In vitro
This study focused on developing analytical methods to detect AOD9604 — a synthetic peptide derived from the C-terminal fragment (residues 177–191) of human growth hormone with an added N-terminal tyrosine — in biological samples for anti-doping purposes. AOD9604 is reported to mimic the lipolytic effects of growth hormone without diabetogenic side effects, making it a candidate performance-enhancing drug banned by WADA. Researchers validated a solid-phase extraction method for detecting AOD9604 in urine, achieving a limit of detection of 50 pg/mL with acceptable linearity, precision (below 20%), specificity, and recovery (62%). The study also characterized in vitro metabolism by incubating AOD9604 in serum and urine, identifying six potential metabolites. Quantification in serum revealed one notably stable metabolite — a peptide fragment consisting of the amino acid sequence CRSVEGSCG — that persisted longer than both the parent compound and other metabolites. The authors suggest that screening for both AOD9604 and this stable metabolite could extend the detection window in doping controls. Limitations include the in vitro nature of the metabolic data, meaning real-world metabolic behavior in human subjects in vivo remains uncharacterized.
Drug testing and analysis · Sep 2014DOI ↗